Your session is about to expire
← Back to Search
Anti-metabolites
Lometrexol + Folic Acid for Advanced Lung Cancer
Phase 2
Waitlist Available
Research Sponsored by Tularik
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Stage IIIB or IV
Histologically confirmed non-small cell lung cancer (NSCLC)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial will combine lometrexol, which may stop or slow the growth of tumor cells, with folic acid. The combination may be an effective treatment for patients with stage IIIB or stage IV non-small cell lung cancer.
Who is the study for?
This trial is for adults with stage IIIB or IV non-small cell lung cancer that's been treated before. They must have a good performance status, no brain metastases, adequate blood counts, and functioning organs. Pregnant women can't join; others must use contraception. No recent other cancers (except certain skin cancers), HIV negative individuals without severe diseases are eligible.Check my eligibility
What is being tested?
The study tests combining lometrexol with folic acid to see if it slows tumor growth in advanced non-small cell lung cancer patients by blocking enzymes needed for the tumors to grow. This phase II trial aims to find out how effective this combination is after previous treatments.See study design
What are the potential side effects?
Potential side effects of lometrexol may include nausea, fatigue, liver issues, and low blood counts which could lead to increased infection risk or bleeding problems. Folic acid is generally well-tolerated but might cause mild stomach upset or allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer is at an advanced stage.
Select...
My lung cancer is confirmed to be non-small cell type.
Select...
My cancer has worsened after one treatment with cisplatin or carboplatin.
Select...
My cancer is diagnosed as large cell carcinoma.
Select...
My cancer is a type called adenosquamous carcinoma.
Select...
My cancer is adenocarcinoma.
Select...
My cancer is squamous cell carcinoma.
Select...
I have a tumor that is at least 1 cm big, not previously treated with radiation or has grown after radiation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
TularikLead Sponsor
6 Previous Clinical Trials
925 Total Patients Enrolled
David TesarowskiStudy ChairTularik
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer is at an advanced stage.I cannot absorb folic acid properly.I do not have any severe illnesses that would stop me from joining the study.My lung cancer is confirmed to be non-small cell type.I have been diagnosed with inflammatory bowel disease.My cancer has worsened after one treatment with cisplatin or carboplatin.My cancer has spread to my brain or its coverings.My cancer is diagnosed as large cell carcinoma.My cancer is a type called adenosquamous carcinoma.My cancer is adenocarcinoma.My cancer is squamous cell carcinoma.I have fluid buildup in my chest or abdomen that is causing symptoms or increasing quickly.I have a condition that prevents my body from absorbing nutrients properly.I haven't had cancer in the past 5 years, except for certain skin cancers or cervical pre-cancer.I have inflammation in my intestines from radiation.I have a tumor that is at least 1 cm big, not previously treated with radiation or has grown after radiation.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the geographic scope of this clinical inquiry?
"Currently, this medical trial is recruiting from 7 different sites located in San Francisco, New Orleans, Houston and other nearby cities. To reduce travel constraints during the study period, it would be wise to choose a local clinic for enrollment."
Answered by AI
What risks are associated with this therapeutic approach?
"While there is some evidence of safety, no data exists that can verify the efficacy of this treatment. Consequently, we assigned it a score of 2 on our risk assessment scale."
Answered by AI
Are there any vacancies still available in this clinical trial?
"According to information hosted on clinicaltrials.gov, this specific medical trial is no longer enrolling patients as the last update was made in 2014. However, there are currently 2037 other trials actively seeking candidates at present."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger